Abstract: The present invention belongs to the field of biomedical chemistry and provides modified peptides and dimers thereof derived from the amino acid sequence of the protein ADAM-12, their compositions, process of synthesis and their use in medicine, specifically in the inhibition of cancer growth and/or the reduction or inhibition of cancer cell invasion and metastasis in different cancers.

Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.

Abstract: The invention relates to peptides of general formula (I): R1-AA-R2??(I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.

Abstract: The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin.

Abstract: A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.

Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.

Abstract: A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.

Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.

Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.

Abstract: The invention relates to a method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and/or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product.

Abstract: The invention relates to peptides of general formula (I): R1-AA-R2 ??(I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.

Abstract: Compounds of formula (I) or their pharmaceutically or biologically acceptable salts are useful as cell penetrating carriers. According to formula (I), below, Val is L-Val or D-Val; Arg is L-Arg, D-Arg or L-(N-methyl)Arg; Pro is L-Pro or D-Pro; Leu is L-Leu or D-Leu; x is an integer from 1 to 20, preferably 3; L1 and L2 are chemical linkers; M1 and M2 are pharmacologically and/or biologically active moieties; and the bond between L1 and M1 and the bond between L2 and M2 are of the known chemical natures, including covalent and ionic. Compared with other previously described carrier peptides, this new family presents several advantages including its non-viral origin, its amphipathic character, its solubility in water and the absence of a cytotoxic effect at high concentrations.